A number of other equities analysts have also recently commented on the company. Credit Suisse Group reiterated a neutral rating and issued a $25.00 target price (down previously from $31.00) on shares of Phibro Animal Health in a report on Wednesday, August 28th. ValuEngine cut Phibro Animal Health from a hold rating to a sell rating in a report on Wednesday, August 28th. Gabelli upgraded Phibro Animal Health from a hold rating to a buy rating and set a $42.00 target price for the company in a report on Wednesday, May 8th. They noted that the move was a valuation call. Bank of America dropped their price objective on Phibro Animal Health from $29.00 to $18.00 and set an underperform rating for the company in a report on Thursday, August 29th. Finally, Guggenheim started coverage on Phibro Animal Health in a report on Thursday, May 23rd. They set a neutral rating for the company. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and one has issued a buy rating to the company. Phibro Animal Health presently has a consensus rating of Hold and a consensus price target of $26.60.
Shares of Phibro Animal Health stock traded up $0.44 on Friday, reaching $21.40. The company had a trading volume of 119,775 shares, compared to its average volume of 182,279. The firm has a market cap of $843.45 million, a price-to-earnings ratio of 13.99, a P/E/G ratio of 4.15 and a beta of 0.82. The company has a debt-to-equity ratio of 1.45, a current ratio of 3.02 and a quick ratio of 1.74. The firm’s 50-day moving average price is $27.61 and its two-hundred day moving average price is $30.25. Phibro Animal Health has a 1 year low of $20.00 and a 1 year high of $44.99.
Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Tuesday, August 27th. The company reported $0.33 EPS for the quarter, missing the Zacks’ consensus estimate of $0.34 by ($0.01). The company had revenue of $203.90 million during the quarter, compared to analysts’ expectations of $206.00 million. Phibro Animal Health had a return on equity of 29.99% and a net margin of 6.59%. Phibro Animal Health’s revenue for the quarter was down 3.7% compared to the same quarter last year. During the same quarter last year, the firm posted $0.46 EPS. As a group, analysts anticipate that Phibro Animal Health will post 1.12 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 25th. Investors of record on Wednesday, September 4th will be issued a dividend of $0.12 per share. This represents a $0.48 dividend on an annualized basis and a yield of 2.24%. The ex-dividend date is Tuesday, September 3rd. Phibro Animal Health’s payout ratio is currently 31.37%.
In other Phibro Animal Health news, Director E Thomas Corcoran acquired 5,000 shares of the company’s stock in a transaction that occurred on Friday, August 30th. The stock was bought at an average price of $21.21 per share, for a total transaction of $106,050.00. Following the acquisition, the director now directly owns 15,000 shares in the company, valued at $318,150. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 50.29% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of PAHC. Fiduciary Management Inc. WI lifted its holdings in shares of Phibro Animal Health by 332.3% in the 2nd quarter. Fiduciary Management Inc. WI now owns 1,073,390 shares of the company’s stock worth $34,102,000 after buying an additional 825,090 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Phibro Animal Health by 315.4% in the 2nd quarter. Janus Henderson Group PLC now owns 956,784 shares of the company’s stock worth $30,397,000 after buying an additional 726,444 shares during the period. Nuveen Asset Management LLC purchased a new stake in shares of Phibro Animal Health in the 2nd quarter worth $17,796,000. Chartwell Investment Partners LLC purchased a new stake in shares of Phibro Animal Health in the 2nd quarter worth $5,067,000. Finally, FMR LLC lifted its holdings in shares of Phibro Animal Health by 82.7% in the 1st quarter. FMR LLC now owns 337,652 shares of the company’s stock worth $11,143,000 after buying an additional 152,853 shares during the period. Institutional investors and hedge funds own 51.74% of the company’s stock.
About Phibro Animal Health
Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.
Featured Story: How the Consumer Price Index (CPI) is calculated?
Receive News & Ratings for Phibro Animal Health Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Phibro Animal Health and related companies with MarketBeat.com’s FREE daily email newsletter.